Evogene Ltd. (EVGN)

Market Cap	9.82M
Revenue (ttm)	6.77M
Net Income (ttm)	-15.21M
Shares Out	6.67M
EPS (ttm)	-2.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	352,237
Open	1.490
Previous Close	1.520
Day's Range	1.460 - 1.630
52-Week Range	0.950 - 7.190
Beta	1.37
Analysts	Strong Buy
Price Target	3.50 (+122.93%)
Earnings Date	May 21, 2025

About EVGN

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 117
• Stock Exchange: NASDAQ
• Ticker Symbol: EVGN
• Website: https://www.evogene.com

Financial Performance

In 2024, Evogene's revenue was $8.51 million, an increase of 50.90% compared to the previous year's $5.64 million. Losses were -$16.49 million, -30.96% less than in 2023.

Analyst Forecast

According to one analyst, the rating for EVGN stock is "Strong Buy" and the 12-month stock price forecast is $3.5.

Price Target

$3.5

(122.93% upside)

Analyst Consensus: Strong Buy